Fig. 2: Capmatinib blocks HGF-mediated p-MET expression, reduces MMP-9 activity and prevents phosphorylation of p-EGFR. Primary keratinocytes from newborn mice were cultured in low calcium (0.05 mM) growth media and transduced with v-rasHa. | Oncogenesis

Fig. 2: Capmatinib blocks HGF-mediated p-MET expression, reduces MMP-9 activity and prevents phosphorylation of p-EGFR. Primary keratinocytes from newborn mice were cultured in low calcium (0.05 mM) growth media and transduced with v-rasHa.

From: Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer

Fig. 2

Cultures were treated with 0.1 nM Capmatinib, followed by administration of 20 ng/ml HGF or vehicle. Total protein was lysed 15 min post HGF treatment. Immunoblotting of p-MET/MET and MET (a) p-EGFR/EGFR (b) in total cell extracts from primary control keratinocytes was conducted. Lower exposure of (Fig. 2a) is also shown in Supplementary data B. c Gelatin zymography of MMP-9 activity in conditioned media from v-rasHa-transduced Tpl2+/+ (WT) and Tpl2−/− (KO) keratinocytes treated with HGF+/− Capmatinib

Back to article page